Study of Pembrolizumab (MK-3475) in Participants With Advanced Urothelial Cancer (MK-3475-052/KEYNOTE-52)



Status:Recruiting
Conditions:Prostate Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:18 - Any
Updated:5/19/2016
Start Date:February 2015
End Date:June 2018
Contact:Toll Free Number
Phone:1-888-577-8839

Use our guide to learn which trials are right for you!

A Phase II Clinical Trial of Pembrolizumab (MK-3475) in Subjects With Advanced/Unresectable or Metastatic Urothelial Cancer

This is a study using pembrolizumab (MK-3475, KEYTRUDA®) for first-line treatment of
participants with advanced/unresectable (inoperable) or metastatic urothelial cancer who are
ineligible for cisplatin-based therapy. The primary study objective is to determine the
objective response rate (ORR) in all participants, in participants whose tumors rely on
programmed cell death ligand 1 (PD-L1) protein (PD-L1-positive tumors), and in participants
with strongly PD-L1-positive tumors.

Participants receiving pembrolizumab who attain a complete response (CR) may consider
stopping trial treatment if they meet criteria for holding therapy. Participants who stop
trial treatment after receiving 24 months of trial treatment for reasons other than
progressive disease (PD) or intolerability, or participants who attain a CR and stop trial
treatment may be eligible for up to one year of retreatment upon experiencing PD.

Inclusion Criteria:

- Histologically- or cytologically-confirmed diagnosis of advanced/unresectable
(inoperable) or metastatic urothelial cancer of the renal pelvis, ureter, bladder, or
urethra (transitional cell and mixed transitional/non-transitional cell histologies)

- Ineligible for cisplatin therapy

- No prior systemic chemotherapy for metastatic disease (adjuvant or neoadjuvant
platinum-based chemotherapy with recurrence >12 months since completion of therapy is
allowed)

- Available tissue from a newly obtained core or excisional biopsy of a tumor lesion
not previously irradiated

- Measureable disease

- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2

- Adequate organ function

- Female participants of childbearing potential have a negative urine or serum
pregnancy test; surgically sterile, or willing to use 2 acceptable methods of birth
control, or abstain from heterosexual activity for the course of the study through
120 days after the last dose of study treatment

- Male participants must be willing to use an adequate method of contraception starting
with the first dose of study medication through 120 days after the last dose of study
treatment

Exclusion Criteria:

- Disease that is suitable for local therapy administered with curative intent

- Currently participating or has participated in a study of an investigational agent
and received study therapy or used an investigational device within 4 weeks prior to
the first dose of study treatment

- Prior anti-cancer monoclonal antibody (mAb) for direct anti-neoplastic treatment
within 4 weeks prior to study Day 1 or who has not recovered from adverse events due
to agents administered more than 4 weeks earlier

- Prior chemotherapy, targeted small molecule therapy, or radiation therapy within 2
weeks prior to study Day 1 or not recovered from AEs due to a previously administered
agent

- Known additional malignancy that is progressing or requires active treatment
excepting basal cell carcinoma of the skin, squamous cell carcinoma of the skin that
has undergone potentially curative therapy, or in situ cancer

- Known active central nervous system (CNS) metastases and/or carcinomatous meningitis

- Active autoimmune disease that has required systemic treatment in past 2 years

- Evidence of interstitial lung disease or active non-infectious pneumonitis

- Active infection requiring systemic therapy

- Pregnant or breastfeeding, or expecting to conceive or father children within the
projected duration of the trial, starting with the screening visit through 120 days
after the last dose of study treatment

- Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent
directed to another co-inhibitory T-cell receptor

- Known human immunodeficiency virus (HIV)

- Known active Hepatitis B or C

- Received a live virus vaccine within 30 days of planned start of study treatment
We found this trial at
34
sites
?
mi
from
Weslaco, TX
Click here to add this to my saved trials
?
mi
from
Albany, NY
Click here to add this to my saved trials
?
mi
from
Aurora, CO
Click here to add this to my saved trials
?
mi
from
Baltimore, MD
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Boston, MA
Click here to add this to my saved trials
?
mi
from
Chicago, IL
Click here to add this to my saved trials
?
mi
from
Cleveland, OH
Click here to add this to my saved trials
?
mi
from
Dallas, TX
Click here to add this to my saved trials
?
mi
from
Fort Worth, TX
Click here to add this to my saved trials
?
mi
from
Houston, TX
Click here to add this to my saved trials
?
mi
from
Indianapolis, IN
Click here to add this to my saved trials
?
mi
from
Jacksonville, FL
Click here to add this to my saved trials
Kirkland, Quebec
Phone: 514-428-8600 / 1-800-567-2594
?
mi
from
Kirkland,
Click here to add this to my saved trials
?
mi
from
Las Vegas, NV
Click here to add this to my saved trials
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
?
mi
from
Minneapolis, MN
Click here to add this to my saved trials
New Brunswick, New Jersey 08901
?
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
New York, NY
Click here to add this to my saved trials
?
mi
from
Niles, IL
Click here to add this to my saved trials
?
mi
from
Norfolk, VA
Click here to add this to my saved trials
?
mi
from
Omaha, NE
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Philadelphia, PA
Click here to add this to my saved trials
?
mi
from
Portland, OR
Click here to add this to my saved trials
?
mi
from
Rochester, MN
Click here to add this to my saved trials
?
mi
from
Sacramento, CA
Click here to add this to my saved trials
?
mi
from
San Antonio, TX
Click here to add this to my saved trials
?
mi
from
Scottsdale, AZ
Click here to add this to my saved trials
?
mi
from
Seattle, WA
Click here to add this to my saved trials
?
mi
from
Silver Spring, MD
Click here to add this to my saved trials
?
mi
from
Tucson, AZ
Click here to add this to my saved trials
?
mi
from
Tulsa, OK
Click here to add this to my saved trials